W

Wave Life Sciences USA

Clinical-stage biotech developing stereopure oligonucleotides

Formulations – Oligonucleotide Synthesis and Chemistry Co-op

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Internship · Spring 2027Lexington, MA, USAIn-person

About the Job

Requirements

  • Currently enrolled in an undergraduate or graduate science program in Chemistry, Biology, Biotechnology, or a related field.
  • Coursework in organic chemistry is required.
  • Understand laboratory best practices and safety protocols.
  • Laboratory experience with common operations, including pipetting, weighing, and centrifugation, is preferred.

Responsibilities

  • Analyze oligonucleotides by liquid chromatography-mass spectrometry, ultra-high-performance liquid chromatography, endotoxin, osmolality, ultraviolet, and pH.
  • Prepare and formulate oligonucleotide samples for in vitro and in vivo biological assays and method development.
  • Use an automated liquid handler (Hamilton Star) for high-throughput, plate-based sample preparation.
  • Assist with management of the oligonucleotide inventory and re-quality-control program.
  • Record and present data in an electronic laboratory notebook.
  • Gain exposure to automated oligonucleotide solid-phase synthesis techniques.
  • Gain exposure to liquid chromatography method development and application.
  • Fulfill compound requests to support Discovery-related activities and ensure sample quality.

Desired Qualifications

  • Coursework in biochemistry and analytical chemistry is a plus.
  • Interest in analytical chemistry.
  • Enthusiasm for DNA/RNA therapeutic development.

About the Company

Wave Life Sciences USA

Clinical-stage biotech developing stereopure oligonucleotides

Wave Life Sciences develops stereopure nucleic acid therapies for genetically defined diseases. Its PRISM platform designs stereopure oligonucleotides that enable RNA interference, antisense silencing, splicing modulation, and RNA editing, including AIMers that recruit ADAR enzymes to edit RNA without changing the DNA. The company funds R&D mainly through partnerships and licensing (notably with GSK) and has programs in conditions like Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity. Its goal is to bring approved RNA medicines to patients by advancing a diversified pipeline and sustaining long-term collaborations that fund development.

Company size
201-500
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2012

Recently Posted Jobs

Explore more opportunities at Wave Life Sciences USA

See more jobs